
    
      This is a randomized, 2-arm, parallel group, double blind study to evaluate the efficacy and
      safety of Canagliflozin (TA-7284) in Japanese patients with type 2 diabetes mellitus, who are
      receiving treatment with insulin therapy on diet and exercise and have inadequate glycemic
      control. The patients will receive either TA-7284 100mg or Placebo orally for 16 weeks.
    
  